NDAORALTABLET
Approved
Mar 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
6/8 — Strong
DIOVAN HCT (valsartan and hydrochlorothiazide) by Novartis is angiotensin 2 receptor antagonists [moa]. Approved for angiotensin 2 receptor blocker [epc]. First approved in 1998.
Drug data last refreshed 33m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIOVAN HCT is a fixed-dose combination of valsartan (an angiotensin II receptor blocker) and hydrochlorothiazide (a thiazide diuretic) indicated for hypertension management. It works by blocking angiotensin II receptors to reduce vasoconstriction and promoting sodium/water excretion to lower blood pressure. This oral tablet formulation provides dual mechanism control in a single daily dose.
$8MPart D
LOE ApproachingDeclining
As a mature product approaching loss of exclusivity with modest $8M spending and low claim volume (8,763 annually), this brand faces significant headwinds and likely operates with a lean commercial team focused on retention.
Mechanism of Action
Angiotensin 2 Receptor Antagonists
Pharmacologic Class:
Angiotensin 2 Receptor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.
Started Oct 2006
601 enrolled
Hypertension
Career Relevance
DIOVAN HCT represents a legacy maintenance franchise with minimal new career growth opportunity; positions are primarily defensive, focused on generic transition management and retention of remaining market share. Working on this product offers exposure to late-lifecycle strategy, managed care negotiation, and portfolio rationalization rather than innovation-driven career advancement.
Brand Manager
Worked on DIOVAN HCT at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.